Ocugen’s Modifier Gene Therapy Targets Dozens of Blindness-Causing Mutations with One Drug
A single drug that could treat inherited blindness regardless of which gene is broken — that is the audacious promise ...
Tag: Ocugen
Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing
Ocugen has quietly reshaped its financial outlook. In May, the company placed $130 million in convertible notes, carrying a 6.75% ...
Ocugen’s Insider and Institutional Conviction Rises as a Dense Timeline of Gene Therapy Catalysts Approaches
Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has ...
Ocugen’s CFO Bets on Her Own Stock as a Packed Conference Schedule Previews a Pivotal Summer
The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week ...
Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge
The divergence between Ocugen's scientific trajectory and its stock price has rarely been starker. The biotech's shares closed at €1.05 ...
Ocugen’s Mutation-Agnostic Gene Therapy Edges Toward FDA Filing as $130M Financing Secures Runway to 2028
Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400, ...
Ocugen’s Data-Driven Countdown: Three Parallel Catalysts Converge in Q3 2026
Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company ...
Ocugen Names Interim CMO as $130M Convertible Fuels Gene Therapy Push Toward FDA Filings
Ocugen has parted ways with its chief medical officer just as the biotech enters a pivotal stretch for its lead ...
Ocugen’s Gene Therapy Candidates Race Toward FDA Filings, But the Market Isn’t Ready to Celebrate
Ocugen is making quiet but meaningful progress across its pipeline of gene therapy programmes, yet the stock tells a more ...
Ocugen Halves Interest Expense as $130M Convertible Refinances High-Cost Debt
Ocugen has pulled off a financing manoeuvre that slashes its interest burden in half, using a $130 million convertible bond ...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
